Global adalimumab market is expected to undergo formidable growth during the forecast period owing to increasing geriatric population and rising prevalence of arthritis around the world. Adalimumab is an anti-TNF drug which is used for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis and ulcerative colitis. Adalimumab lowers the chances of inflammatory response by binding to a TNFα.They were first approved by the U.S. Food and Drug Administration in December 2002. Adalimumab are currently being marketed in over 60 countries around the world.

Moreover, companies are undergoing extensive clinical trials and R&D activities which is acting as a major growth factor for global adalimumab market. The reimbursement coverage provided in various countries are further expected to fuel the market growth through 2025. However, adalimumab market is also facing some key issues. These are expensive drugs owing to their biologic nature. This may hamper the market growth. Also, patent expiry from many companies might pose a challenge for the market.

Global adalimumab market can be segmented based on based on type, type of disease, route of administration, end users, distribution channel and region. Based on type of diseases, the market is categorized into rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn’s disease and ulcerative colitis. Among them, the rheumatoid arthritis is expected to dominate the global market owing to high prevalence among elderly population.

Regionally, North America is expected to dominate the global adalimumab market followed by Europe. The advanced healthcare infrastructure and well-organized regulatory framework in these two regions is making them a lucrative market for adalimumab manufacturers.

Major companies operating in global adalimumab market include Abbvie Inc., Pfizer Inc., Amgen Inc., Novartis AG, Mylan N.V.6, Samsung Bioepis Co Ltd, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Cadila Healthcare Ltd., Hetero Healthcare Ltd., Bristol-Myers Squibb, Hoffmann-La Roche Ltd., Glenmark Pharmaceuticals and Torrent Pharmaceuticals Ltd., among others. The market players are undergoing extensive clinical trials to test the safety and efficacy of the adalimumab in treatment of various diseases.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021–2025

Objective of the Study:

  • To analyse and forecast the market size of global adalimumab market.
  • To forecast global adalimumab market based on based on type, type of disease, route of administration, end users, distribution channel, company and regional distribution.
  • To identify drivers and challenges for global adalimumab market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global adalimumab market.
  • To identify and analyse the profile of leading players operating in the global adalimumab market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of adalimumab manufacturing companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global adalimumab market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.


Key Target Audience:

  • Adalimumab manufacturers, companies, partners, hospitals pharmacy/retail pharmacy and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to adalimumab
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as adalimumab manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global adalimumab market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Adalimumab Market, By Type:
    • Adalimumab
    • Adalimumab Biosimilar
  • Global Adalimumab Market, By Type of Disease:
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Psoriasis
    • Crohn’s Disease
    • Ulcerative Colitis
  • Global Adalimumab Market, By Route of Administration:
    • Parenteral
    • Others
  • Global Adalimumab Market, By End Users:
    • Hospitals
    • Specialty Clinics
    • Others
  • Global Adalimumab Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Others
  • Global Adalimumab Market, By Region:
    • Asia-Pacific
      • China
      • Japan
      • India 
      • South Korea
      • Australia
      • Singapore
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • North America
      • United States
      • Mexico
      • Canada
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global adalimumab market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com  

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Adalimumab Market

4.    Executive Summary

5.    Voice of Customer

6.    Global Adalimumab Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Type (Adalimumab, Adalimumab Biosimilar)

6.2.2.     By Type of Disease (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis)

6.2.3.     By Route of Administration (Parenteral, Others)

6.2.4.     By End Users (Hospitals, Specialty Clinics, Others)

6.2.5.     By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)

6.2.6.     By Company (2019)

6.2.7.     By Region

6.3.  Market Attractiveness Index

7.    Asia-Pacific Adalimumab Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Type of Disease

7.2.2.     By Route of Administration

7.2.3.     By End Users

7.2.4.     By Distribution Channel

7.2.5.     By Country

7.3.  Market Attractiveness Index

7.4.  Asia-Pacific: Country Analysis

7.4.1.     China Adalimumab Market Outlook

7.4.1.1.         Market Size & Forecast

7.4.1.1.1.             By Value

7.4.1.2.         Market Share & Forecast

7.4.1.2.1.             By Type of Disease

7.4.1.2.2.             By Route of Administration

7.4.1.2.3.             By End Users

7.4.1.2.4.             By Distribution Channel

7.4.2.     India Adalimumab Market Outlook

7.4.2.1.         Market Size & Forecast

7.4.2.1.1.             By Value

7.4.2.2.         Market Share & Forecast

7.4.2.2.1.             By Type of Disease

7.4.2.2.2.             By Route of Administration

7.4.2.2.3.             By End Users

7.4.2.2.4.             By Distribution Channel

7.4.3.     Japan Adalimumab Market Outlook

7.4.3.1.         Market Size & Forecast

7.4.3.1.1.             By Value

7.4.3.2.         Market Share & Forecast

7.4.3.2.1.             By Type of Disease

7.4.3.2.2.             By Route of Administration

7.4.3.2.3.             By End Users

7.4.3.2.4.             By Distribution Channel

7.4.4.     South Korea Adalimumab Market Outlook

7.4.4.1.         Market Size & Forecast

7.4.4.1.1.             By Value

7.4.4.2.         Market Share & Forecast

7.4.4.2.1.             By Type of Disease

7.4.4.2.2.             By Route of Administration

7.4.4.2.3.             By End Users

7.4.4.2.4.             By Distribution Channel

7.4.5.     Singapore Adalimumab Market Outlook

7.4.5.1.         Market Size & Forecast

7.4.5.1.1.             By Value

7.4.5.2.         Market Share & Forecast

7.4.5.2.1.             By Type of Disease

7.4.5.2.2.             By Route of Administration

7.4.5.2.3.             By End Users

7.4.5.2.4.             By Distribution Channel

7.4.6.     Australia Adalimumab Market Outlook

7.4.6.1.         Market Size & Forecast

7.4.6.1.1.             By Value

7.4.6.2.         Market Share & Forecast

7.4.6.2.1.             By Type of Disease

7.4.6.2.2.             By Route of Administration

7.4.6.2.3.             By End Users

7.4.6.2.4.             By Distribution Channel

8.    Europe Adalimumab Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type of Disease

8.2.2.     By Route of Administration

8.2.3.     By End Users

8.2.4.     By Distribution Channel

8.2.5.     By Country

8.3.  Market Attractiveness Index

8.4.  Europe: Country Analysis

8.4.1.     France Adalimumab Market Outlook

8.4.1.1.         Market Size & Forecast

8.4.1.1.1.             By Value

8.4.1.2.         Market Share & Forecast

8.4.1.2.1.             By Type of Disease

8.4.1.2.2.             By Route of Administration

8.4.1.2.3.             By End Users

8.4.1.2.4.             By Distribution Channel

8.4.2.     Germany Adalimumab Market Outlook

8.4.2.1.         Market Size & Forecast

8.4.2.1.1.             By Value

8.4.2.2.         Market Share & Forecast

8.4.2.2.1.             By Type of Disease

8.4.2.2.2.             By Route of Administration

8.4.2.2.3.             By End Users

8.4.2.2.4.             By Distribution Channel

8.4.3.     United Kingdom Adalimumab Market Outlook

8.4.3.1.         Market Size & Forecast

8.4.3.1.1.             By Value

8.4.3.2.         Market Share & Forecast

8.4.3.2.1.             By Type of Disease

8.4.3.2.2.             By Route of Administration

8.4.3.2.3.             By End Users

8.4.3.2.4.             By Distribution Channel

8.4.4.     Italy Adalimumab Market Outlook

8.4.4.1.         Market Size & Forecast

8.4.4.1.1.             By Value

8.4.4.2.         Market Share & Forecast

8.4.4.2.1.             By Type of Disease

8.4.4.2.2.             By Route of Administration

8.4.4.2.3.             By End Users

8.4.4.2.4.             By Distribution Channel

8.4.5.     Spain Adalimumab Market Outlook

8.4.5.1.         Market Size & Forecast

8.4.5.1.1.             By Value

8.4.5.2.         Market Share & Forecast

8.4.5.2.1.             By Type of Disease

8.4.5.2.2.             By Route of Administration

8.4.5.2.3.             By End Users

8.4.5.2.4.             By Distribution Channel

9.    North America Adalimumab Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type of Disease

9.2.2.     By Route of Administration

9.2.3.     By End Users

9.2.4.     By Distribution Channel

9.2.5.     By Country

9.3.  Market Attractiveness Index

9.4.  North America: Country Analysis

9.4.1.     United States Adalimumab Market Outlook

9.4.1.1.         Market Size & Forecast

9.4.1.1.1.             By Value

9.4.1.2.         Market Share & Forecast

9.4.1.2.1.             By Type of Disease

9.4.1.2.2.             By Route of Administration

9.4.1.2.3.             By End Users

9.4.1.2.4.             By Distribution Channel

9.4.2.     Mexico Adalimumab Market Outlook

9.4.2.1.         Market Size & Forecast

9.4.2.1.1.             By Value

9.4.2.2.         Market Share & Forecast

9.4.2.2.1.             By Type of Disease

9.4.2.2.2.             By Route of Administration

9.4.2.2.3.             By End Users

9.4.2.2.4.             By Distribution Channel

9.4.3.     Canada Adalimumab Market Outlook

9.4.3.1.         Market Size & Forecast

9.4.3.1.1.             By Value

9.4.3.2.         Market Share & Forecast

9.4.3.2.1.             By Type of Disease

9.4.3.2.2.             By Route of Administration

9.4.3.2.3.             By End Users

9.4.3.2.4.             By Distribution Channel

10.  South America Adalimumab Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Type of Disease

10.2.2.  By Route of Administration

10.2.3.  By End Users

10.2.4.  By Distribution Channel

10.2.5.  By Country

10.3.              Market Attractiveness Index

10.4.              South America: Country Analysis

10.4.1.  Brazil Adalimumab Market Outlook

10.4.1.1.      Market Size & Forecast

10.4.1.1.1.           By Value

10.4.1.2.      Market Share & Forecast

10.4.1.2.1.           By Type of Disease

10.4.1.2.2.           By Route of Administration

10.4.1.2.3.           By End Users

10.4.1.2.4.           By Distribution Channel

10.4.2.  Argentina Adalimumab Market Outlook

10.4.2.1.      Market Size & Forecast

10.4.2.1.1.           By Value

10.4.2.2.      Market Share & Forecast

10.4.2.2.1.           By Type of Disease

10.4.2.2.2.           By Route of Administration

10.4.2.2.3.           By End Users

10.4.2.2.4.           By Distribution Channel

10.4.3.  Colombia Adalimumab Market Outlook

10.4.3.1.      Market Size & Forecast

10.4.3.1.1.           By Value

10.4.3.2.      Market Share & Forecast

10.4.3.2.1.           By Type of Disease

10.4.3.2.2.           By Route of Administration

10.4.3.2.3.           By End Users

10.4.3.2.4.           By Distribution Channel

11.  Middle East and Africa Adalimumab Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Type of Disease

11.2.2.  By Route of Administration

11.2.3.  By End Users

11.2.4.  By Distribution Channel

11.2.5.  By Country

11.3.              Market Attractiveness Index

11.4.              MEA: Country Analysis

11.4.1.  South Africa Adalimumab Market Outlook

11.4.1.1.      Market Size & Forecast

11.4.1.1.1.           By Value

11.4.1.2.      Market Share & Forecast

11.4.1.2.1.           By Type of Disease

11.4.1.2.2.           By Route of Administration

11.4.1.2.3.           By End Users

11.4.1.2.4.           By Distribution Channel

11.4.2.  Saudi Arabia Adalimumab Market Outlook

11.4.2.1.      Market Size & Forecast

11.4.2.1.1.           By Value

11.4.2.2.      Market Share & Forecast

11.4.2.2.1.           By Type of Disease

11.4.2.2.2.           By Route of Administration

11.4.2.2.3.           By End Users

11.4.2.2.4.           By Distribution Channel

11.4.3.  UAE Adalimumab Market Outlook

11.4.3.1.      Market Size & Forecast

11.4.3.1.1.           By Value

11.4.3.2.      Market Share & Forecast

11.4.3.2.1.           By Type of Disease

11.4.3.2.2.           By Route of Administration

11.4.3.2.3.           By End Users

11.4.3.2.4.           By Distribution Channel

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Competition Outlook

14.2.              Players Profiled (Leading Companies)

14.2.1.  Abbvie Inc.

14.2.2.  Pfizer Inc.

14.2.3.  Amgen Inc.

14.2.4.  Novartis AG

14.2.5.  Mylan N.V.6

14.2.6.  Samsung Bioepis Co Ltd.

14.2.7.  Boehringer Ingelheim International GmbH

14.2.8.  Merck & Co., Inc.

14.2.9.  Cadila Healthcare Ltd.

14.2.10.                Hetero Healthcare Ltd.

14.2.11.                Bristol-Myers Squibb

14.2.12.                Hoffmann-La Roche Ltd.

14.2.13.                Glenmark Pharmaceuticals

14.2.14.                Torrent Pharmaceuticals Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com